KR102643280B1 - 변형된 인자 h 결합 단백질 - Google Patents

변형된 인자 h 결합 단백질 Download PDF

Info

Publication number
KR102643280B1
KR102643280B1 KR1020197008694A KR20197008694A KR102643280B1 KR 102643280 B1 KR102643280 B1 KR 102643280B1 KR 1020197008694 A KR1020197008694 A KR 1020197008694A KR 20197008694 A KR20197008694 A KR 20197008694A KR 102643280 B1 KR102643280 B1 KR 102643280B1
Authority
KR
South Korea
Prior art keywords
gly
ala
lys
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197008694A
Other languages
English (en)
Korean (ko)
Other versions
KR20190064577A (ko
Inventor
크리스토프 엠 탕
Original Assignee
옥스포드 유니버시티 이노베이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 옥스포드 유니버시티 이노베이션 리미티드 filed Critical 옥스포드 유니버시티 이노베이션 리미티드
Publication of KR20190064577A publication Critical patent/KR20190064577A/ko
Application granted granted Critical
Publication of KR102643280B1 publication Critical patent/KR102643280B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020197008694A 2016-08-31 2017-08-31 변형된 인자 h 결합 단백질 Active KR102643280B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1614687.0A GB201614687D0 (en) 2016-08-31 2016-08-31 fHbp scaffold
GB1614687.0 2016-08-31
PCT/GB2017/052535 WO2018042178A1 (en) 2016-08-31 2017-08-31 Modified factor h binding protein

Publications (2)

Publication Number Publication Date
KR20190064577A KR20190064577A (ko) 2019-06-10
KR102643280B1 true KR102643280B1 (ko) 2024-03-05

Family

ID=57119942

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008694A Active KR102643280B1 (ko) 2016-08-31 2017-08-31 변형된 인자 h 결합 단백질

Country Status (13)

Country Link
US (1) US12497432B2 (enExample)
EP (1) EP3506934A1 (enExample)
JP (1) JP7525093B2 (enExample)
KR (1) KR102643280B1 (enExample)
CN (1) CN109890412B (enExample)
AU (1) AU2017319218B2 (enExample)
BR (1) BR112019003957A2 (enExample)
CA (1) CA3035159A1 (enExample)
GB (2) GB201614687D0 (enExample)
IL (1) IL265078B2 (enExample)
MX (1) MX420767B (enExample)
WO (1) WO2018042178A1 (enExample)
ZA (1) ZA201901862B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110903400A (zh) * 2019-11-08 2020-03-24 苏州微超生物科技有限公司 B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用
CN111533792B (zh) * 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
JPWO2022071291A1 (enExample) * 2020-09-29 2022-04-07
IN202321021121A (enExample) * 2023-03-24 2024-04-19

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024954A2 (en) 2004-09-01 2006-03-09 Novartis Vaccines And Diagnostics Srl Domains and epitopes of meningococcal protein nmb1870
WO2007060548A2 (en) * 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2016083583A1 (en) * 2014-11-28 2016-06-02 Crucell Holland B.V. Meningitis b vaccine

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
AU2003274511B2 (en) * 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
NZ540620A (en) * 2002-12-10 2009-03-31 Lorantis Ltd Stabilized immunogenic HBc chimer particles
JP4827726B2 (ja) * 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群に対する注射可能ワクチン
RU2378010C2 (ru) * 2003-10-02 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Жидкие вакцины для множественных серогрупп менингококков
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
EP1778725B1 (en) * 2004-07-23 2010-12-29 Novartis Vaccines and Diagnostics S.r.l. Polypeptides for oligomeric assembly of antigens
US9034345B2 (en) * 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US9579372B2 (en) * 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
EP2265640B1 (en) * 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
EP2296699A4 (en) * 2008-05-30 2013-11-13 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army POLYVALENT MENINGOCOCCULAR FUEL WITH NATIVE OUTER MEMBRANE VESICLES, METHOD OF MANUFACTURE AND USE
WO2009150531A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
CA2733943A1 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
BRPI1009828A2 (pt) * 2009-03-24 2019-03-12 Novartis Ag adjuvante de proteína de ligação de fator h meningocócica
AU2010242905B2 (en) * 2009-04-30 2014-10-23 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHbp) and methods of use
NZ598458A (en) * 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
BR112012010531A2 (pt) * 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
BR112012022669A2 (pt) * 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
BR112012024348B1 (pt) * 2010-03-30 2022-11-08 Children's Hospital & Research Center At Oakland Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada
WO2011125015A2 (en) * 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
US10478483B2 (en) * 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
SG187912A1 (en) * 2010-09-10 2013-04-30 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
WO2013098589A1 (en) * 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
ES2750366T3 (es) * 2012-03-08 2020-03-25 Glaxosmithkline Biologicals Sa Ensayo de potencia in vitro para vacunas meningocócicas basadas en proteína
SA115360586B1 (ar) * 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US8986710B2 (en) * 2012-03-09 2015-03-24 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RU2644340C2 (ru) * 2012-06-14 2018-02-08 Новартис Аг Вакцины для менингококка серогруппы х
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
WO2014136064A2 (en) * 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
WO2014140562A1 (en) * 2013-03-14 2014-09-18 Isis Innovation Limited Immunogenic composition to neisseria
CN105492021B (zh) * 2013-09-08 2018-12-04 辉瑞公司 脑膜炎奈瑟氏球菌组合物及其方法
AU2015222121B2 (en) * 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
CN119613509A (zh) * 2014-07-23 2025-03-14 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
US10888611B2 (en) * 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
MX372587B (es) * 2017-01-31 2020-04-17 Pfizer Composiciones de neisseria meningitidis y metodos respectivos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024954A2 (en) 2004-09-01 2006-03-09 Novartis Vaccines And Diagnostics Srl Domains and epitopes of meningococcal protein nmb1870
WO2007060548A2 (en) * 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2016083583A1 (en) * 2014-11-28 2016-06-02 Crucell Holland B.V. Meningitis b vaccine

Also Published As

Publication number Publication date
AU2017319218A1 (en) 2019-04-18
AU2017319218B2 (en) 2021-10-28
BR112019003957A2 (pt) 2019-06-25
ZA201901862B (en) 2020-09-30
GB2568440A (en) 2019-05-15
CA3035159A1 (en) 2018-03-08
CN109890412A (zh) 2019-06-14
IL265078A (enExample) 2019-04-30
IL265078B1 (en) 2023-04-01
GB201903866D0 (en) 2019-05-08
EP3506934A1 (en) 2019-07-10
WO2018042178A1 (en) 2018-03-08
GB2568440B (en) 2022-08-17
MX420767B (es) 2025-02-10
CN109890412B (zh) 2025-04-04
US20220112249A1 (en) 2022-04-14
JP2019526261A (ja) 2019-09-19
JP7525093B2 (ja) 2024-07-30
GB201614687D0 (en) 2016-10-12
IL265078B2 (en) 2023-08-01
NZ751995A (en) 2024-03-22
US12497432B2 (en) 2025-12-16
MX2019002248A (es) 2019-09-18
KR20190064577A (ko) 2019-06-10
AU2017319218A2 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
KR102643280B1 (ko) 변형된 인자 h 결합 단백질
JP5676458B2 (ja) 変異ｈ因子結合タンパク質を含むワクチン組成物
AU2019318120B2 (en) Modified meningococcal fHbp polypeptides
ITMI20081633A1 (it) Immunogeni di proteine che legano il fattore h.
AU2013276083B2 (en) Vaccines for serogroup X meningococcus
AU2017321039B2 (en) Vaccines for Neisseria gonorrhoeae
Jing et al. Oligomerization of IC43 resulted in improved immunogenicity and protective efficacy against Pseudomonas aeruginosa lung infection
AU2013351182C1 (en) Pseudomonas antigens and antigen combinations
US20190290748A1 (en) Antigens and antigen combinations
ES2912751T3 (es) Composiciones inmunogénicas y vacunas derivadas de proteínas receptoras de superficie bacteriana
RU2773464C1 (ru) Модифицированный белок, связывающий фактор н
OA19655A (en) Modified factor H binding protein.
Hartsock et al. Antiadhesin peptide-based vaccines for Pseudomonas aeruginosa
EA046480B1 (ru) МОДИФИЦИРОВАННЫЕ ПОЛИПЕПТИДЫ МЕНИНГОКОККОВОГО fHbp

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190326

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200828

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220914

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230619

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220914

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230619

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230214

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200828

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20231222

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20231120

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230619

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230214

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200828

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240228

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240229

End annual number: 3

Start annual number: 1

PG1601 Publication of registration